Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).